Tamoxifen response in primary breast cancer with special reference to tumour-specific VEGF-A and VEGFR2
Background: Treatment of primary breast cancer is individualised and adjuvant systemic treatment is delivered to most patients after surgery. Oestrogen receptor (ER) status and progesterone receptor status (PR) can define patients who would benefit from adjuvant endocrine therapy with tamoxifen (TAM) alone or as chemo-endocrine therapy. In spite of adjuvant treatment with TAM, some patients with h
